Blue Shield of California Covers Plus Therapeutics' CNSide® Assay, Expanding Access to 81 Million Lives
Summary
This agreement with Blue Shield of California significantly expands market access for Plus Therapeutics' CNSide® Cerebrospinal Fluid Assay, adding 6 million covered lives and bringing the total to 81 million. This commercial milestone is particularly important for Plus Therapeutics, which recently reported a significant net loss and going concern doubts in its last 10-K. The expanded coverage is expected to accelerate adoption of CNSide across oncology centers by reducing reimbursement barriers, directly impacting the product's commercial momentum and potential revenue generation. Traders will closely monitor CNSide adoption rates and the company's progress towards its 2026 target of 150 million covered lives as key indicators of financial improvement.
At the time of this announcement, PSTV was trading at $5.95 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $41.1M. The 52-week trading range was $2.90 to $23.43. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.